Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLONTALE: mFOLFOX6 plus nivolumab in untreated unresectable or recurrent esophageal cancer
jRCTs031230630Phase 2Active, not recruiting
- Start
- Feb 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab, oxaliplatin, fluorouracil and folinic acid in esophageal cancer, Esophageal Squamous Cell Carcinoma (ESCC) and esophageal adenosquamous carcinoma (ASC). Primary endpoint: Objective Response Rate. Started Feb 2024; status: active, not recruiting.
02
Drugs
03
Conditions
esophageal cancerEsophageal Squamous Cell Carcinoma (ESCC)esophageal adenosquamous carcinoma (ASC)
Beyond the preview
Go deeper on jRCTs031230630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230630.